
Opinion|Videos|May 14, 2024
Strategies to Enhance CDK4/6 Inhibitor Adherence in mBC
Heather Moore, BCOP, CPP, PharmD, discusses patient adherence to CDK4/6 inhibitors in clinical practice, emphasizing the importance of educating patients on drug efficacy and potential toxicities, monitoring for adverse events, and following up with patients to ensure better adherence.
Advertisement
Episodes in this series

Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
3
Strengthening Neurology Care Through Clinical Pharmacy Integration and Collaborative Practice
4
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
5



























